Communiqués NetraMark Holdings Inc. OTC Markets

Actions

AINMF

CA64119M1059

Logiciels

Marché Fermé - OTC Markets 18:53:37 03/09/2026			Varia. 5j.	Varia. 1 janv.
0,3985 ^USD	-7,88 %		-7,88 %	-49,89 %

01/09	Netramark Holdings Inc. annonce la nomination de Keith M. Fournier à son conseil d'administration	CI
14/08	NetraMark Holdings Inc. publie ses résultats pour le troisième trimestre et les neuf mois clos le 30 juin 2026	CI

Communiqués

08/09	NetraMark Appoints Former Global Atlantic Investment Office President and Scotiabank U.S. CEO Kevin Felix as Strategic Advisor	AQ
01/09	NetraMark Strengthens Board of Directors with Appointment of Veteran Pharmaceutical Executive Dr. Keith Fournier	AQ
27/08	NetraMark to Participate in the H.C. Wainwright 28th Annual Global Investment Conference	AQ
20/08	NetraMark Corporate Update Highlights Record C$3.4 Million in Fiscal 2026 Contract Bookings, Up 645% from Previous Annual High	AQ
13/07	NetraMark Engages AM Public Relations to Support Strategic Communications and Market Awareness	AQ
09/07	NetraMark Signs New Contract To Analyze Phase 2 Neurodegeneration Trial Data With Contract Research Organization Partner	AQ
29/06	NetraMark Signs New NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company	AQ
09/06	NetraMark Announces Presentation at Sidoti Small Cap Conference on June 18, 2026	AQ
25/05	Upcoming Meeting Dates - May 25, 2026	NE
20/05	NetraMark to Present at the American Society of Clinical Psychopharmacology Annual Meeting	AQ
14/05	NetraMark Provides Second Quarter Update and Highlights Continued Commercial, Scientific, Regulatory and Capital Markets Momentum	AQ
07/05	NetraMark Announces Change To Board Of Directors	AQ
05/05	NetraMark Holdings Inc. (AIAI) ouvre les marchés	NE
05/05	NetraMark Holdings Inc. (AIAI) Opens the Market	NE
04/05	NetraMark Appoints Dr. Panteli Theocharous As Fractional Chief Medical Officer, Strengthening Clinical Leadership To Accelerate Global Adoption of NetraAI	AQ
30/04	NetraMark To Open The Market At The Toronto Stock Exchange On May 5, 2026	AQ
22/04	NetraMark Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs	AQ
20/04	Netramark Comments on U.S. Executive Order to Accelerate Treatments for Serious Mental Illness and Highlights the Need for Regulatory‑Grade Trial Design in Psychedelic Development	AQ
09/04	Netramark-Authored, Peer-Reviewed Article Suggests Psychedelics Might Not Only Affect Brain Chemistry, They May Also Involve Quantum-Level Processes Inside the Brain	AQ
25/03	NetraMark Announces Strategic Oncology Research Collaboration with Fondazione per la Medicina Personalizzata to Analyze Landmark ROME Trial Dataset	AQ
19/03	NetraMark Unveils AI-Discovered Treatment-Responsive Subgroups in A4 Alzheimer’s Trial at AD/PD Conference	AQ
11/03	NetraMark Signs Contract With Global Biopharmaceutical Company to Analyze Phase 2 Depression Trial Data	AQ